Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
114 hedge funds and large institutions have $1.47B invested in Fusion Pharmaceuticals Inc. Common Shares in 2024 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 28 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
152% more capital invested
Capital invested by funds: $584M → $1.47B (+$889M)
132% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 28
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
48% more funds holding
Funds holding: 77 → 114 (+37)
43% less call options, than puts
Call options by funds: $48M | Put options by funds: $84.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$50.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$48.7M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$45.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$14.1M |
| 5 |
Millennium Management
New York
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$41.6M |
| 2 |
O
OrbiMed
New York
|
-$30M |
| 3 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$28.3M |
| 4 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$11.9M |
| 5 |
AG
Artal Group
Luxembourg
|
-$9.66M |
FUSN Hedge Fund Activity: Q1 2024 in Review
114 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2024, worth a combined $1.47B — up 152% from $584M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new FUSN positions and 28 closed out — a net gain of 37 holders — while 25 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $50.1M. The largest seller was Fidelity Investments, cutting an estimated $41.6M.
- 114 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2024, up from 77 in Q4 2023.
- Funds reported $1.47B of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2024, up 152% quarter-over-quarter.
- 65 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2024 and 28 closed out, a net change of +37 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2024 was Fidelity International, an estimated $50.1M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2024 was Fidelity Investments, an estimated $41.6M sold.
Based on aggregated 13F filings for Q1 2024.